Clinical Trial List | New Mexico Cancer Care Alliance

Type of Cancer
Clinical Trial Site

Last updated on Monday, 6 July 2020

Christus St Vincent Regional Cancer Center

Trial #	Type	Study Status	Status Date	Title
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Alliance A011502	Breast Adjuvant	Open Active	2017-05-03	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Alliance A011401	Supportive	Open Active	2016-09-29	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Alliance Foundation Trials AFT-19	GU Prostate Advanced	Open Active	2017-12-19	Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Lovelace Medical Center-Saint Joseph Square

Trial #	Type	Study Status	Status Date	Title
Alliance A071701	Brain Advanced	Open Active	2020-05-21	Alliance A071701: Genomically-Guided Treatment Trial in Brain Metastases
Alliance A011502	Breast Adjuvant	Open Active	2017-05-19	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-03-27	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
SWOG S1706	Breast Neoadjuvant	Open Active	2019-06-24	SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Alliance Foundation Trials AFT-25	Breast Other	Open Active	2019-04-05	Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Alliance A021502	GI Colorectal Adjuvant	Open Active	2018-10-12	Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S0820	GI Colorectal Prevention	Open Active	2018-07-27	SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
ECOG-ACRIN EA2165	GI Other	Open Active	2019-04-15	ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
SWOG S1815	GI Other	Open Active	2020-06-22	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
INST 96144	Ill Defined	Open Active	2015-07-28	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-05-12	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-04-09	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
SWOG S1616	Skin Melanoma Advanced	Open Active	2019-07-02	SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C1	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-M	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1C	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
Alliance A011401	Supportive	Open Active	2016-09-17	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001A	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001B	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001C	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001D	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********

Lovelace Radiation Oncology

Trial #	Type	Study Status	Status Date	Title
NSABP B-51	Breast Adjuvant	Open Active	2017-04-13	NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
Alliance A221505	Breast Advanced	Open Active	2018-04-10	Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
CCTG MA.39	Breast Neoadjuvant	Open Active	2018-10-10	CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706	Breast Neoadjuvant	Open Active	2019-06-24	SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
INST LWH 1806	Breast Other	Open Active	2019-03-14	INST LWH 1806: TARGIT New Mexico
ECOG-ACRIN EA2165	GI Other	Open Active	2019-04-15	ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
NRG Oncology NRG-GU005	GU Prostate Advanced	Open Active	2018-02-21	NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
GOG 0263	GYN Cervical Adjuvant	Open Active	2017-06-02	GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
RTOG 0724/GOG-0724	GYN Cervical Adjuvant	Open Active	2017-06-07	RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
WFU WF-1801	Supportive	Open Active	2019-04-01	Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Lovelace Respiratory Research Institute

Trial #	Type	Study Status	Status Date	Title
LRRI #1054101	Lung Ancillary	Open Active	2001-03-01	LRRI #1054101: Defining Lung Cancer Risk in Current and Former Cigarette Smokers: Risk Factors for Epigenetic Silencing of Lung Cancer Genes

Lovelace Women's Hospital

Trial #	Type	Study Status	Status Date	Title
Alliance A011202	Breast Adjuvant	Open Active	2020-05-27	Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-25	Breast Other	Open Active	2019-04-05	Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
INST LWH 1806	Breast Other	Open Active	2019-03-14	INST LWH 1806: TARGIT New Mexico
INST UNM CR1801	Multiple Sites	Open Active	2018-09-04	INST UNM CR1801: Assessment of Intraoperative Radiofrequency Spectroscopy For Improving Lumpectomy Outcomes with Respect to Re-excision Rates and Lumpectomy Size
Alliance A011401	Supportive	Open Active	2017-11-08	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Memorial Medical Center

Trial #	Type	Study Status	Status Date	Title
Alliance A011502	Breast Adjuvant	Open Active	2017-05-04	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
NSABP B-51	Breast Adjuvant	Open Active	2017-01-26	NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-03-27	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
INST University of Arizona 1807	Breast Advanced	Open Active	2020-02-17	INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
NRG Oncology NRG-BR004	Breast Advanced	Open Active	2019-09-24	NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
CCTG MA.39	Breast Neoadjuvant	Open Active	2018-08-21	CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
Alliance Foundation Trials AFT-25	Breast Other	Open Active	2019-03-27	Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
SWOG S1703	Breast Other	Open Active	2020-04-28	SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
NRG-GI005	GI Other	Open Active	2020-06-03	NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
SWOG S1815	GI Other	Open Active	2020-06-22	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Alliance Foundation Trials AFT-19	GU Prostate Advanced	Open Active	2017-12-19	Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Pharm 010-00	GU Prostate Advanced	Open Active	2020-03-04	Merck 010-00: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) PlusOlaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
GOG 0263	GYN Cervical Adjuvant	Open Active	2011-02-07	GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
NRG Oncology NRG-GY005	GYN Other	Open Active	2019-06-24	NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
ECOG-ACRIN NHLBI-MDS	Hematology Other	Open Active	2020-05-18	ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
UNM 1709	Ill Defined	Open Active	2019-07-02	INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-04-21	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-03-26	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
SWOG S1800A	Lung NSCLC Advanced	Open Active	2020-04-08	SWOG S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
SWOG S1900A	Lung NSCLC Advanced	Open Active	2019-03-26	SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1900C	Lung NSCLC Advanced	Open Active	2020-05-05	SWOG S1900C: A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-Study)
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C1	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-M	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-Z1C	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
DCP-001B	Supportive	Open Active	2017-05-24	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
Alliance A011401	Supportive	Open Active	2016-12-16	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001	Supportive	Open Active	2017-05-24	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001A	Supportive	Open Active	2017-05-24	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
ECOG-ACRIN E1Q11	Supportive	Open Active	2018-04-18	ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship
DCP-001D	Supportive	Open Active	2017-05-24	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001C	Supportive	Open Active	2017-05-24	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********

New Mexico Oncology Hematology Consultants

Trial #	Type	Study Status	Status Date	Title
Alliance A011502	Breast Adjuvant	Open Active	2017-05-04	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Alliance A221505	Breast Advanced	Open Active	2018-04-10	Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-03-27	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
NSABP B-51	Breast Adjuvant	Open Active	2016-10-20	NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance Foundation Trials AFT-19	GU Prostate Advanced	Open Active	2017-12-19	Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Pharm PrTK03	GU Prostate Adjuvant	Open Active	2017-06-28	Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
SWOG S1815	GI Other	Open Active	2020-06-22	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
SWOG S0820	GI Colorectal Prevention	Open Active	2018-09-14	SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
CCTG MA.39	Breast Neoadjuvant	Open Active	2018-11-05	CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
NRG Oncology NRG-BR004	Breast Advanced	Open Active	2019-12-18	NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
UNM 1709	Ill Defined	Open Active	2019-07-02	INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 96144	Ill Defined	Open Active	2014-12-09	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
Pharm INCB 18424-MA-GD-301	Hematology Stem Cell Transplant	Open Active	2019-01-29	Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
NRG Oncology NRG-HN004	Head And Neck Advanced	Open Active	2019-03-20	NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
NRG Oncology NRG-GU005	GU Prostate Advanced	Open Active	2018-01-29	NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
SWOG S1801	Skin Melanoma Advanced	Open Active	2020-05-06	SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
SWOG S1800A	Lung NSCLC Advanced	Open Active	2020-04-08	SWOG S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-04-17	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-05-17	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-C1	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1C	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-M	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

NMOHC Gallup

Trial #	Type	Study Status	Status Date	Title
INST 96144	Ill Defined	Open Active	2018-06-18	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives

Presbyterian Medical Group

Trial #	Type	Study Status	Status Date	Title
Alliance A011502	Breast Adjuvant	Open Active	2017-05-08	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Alliance A011202	Breast Adjuvant	Open Active	2020-05-27	Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
SWOG S1703	Breast Other	Open Active	2020-03-02	SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
NRG Oncology NRG-BR004	Breast Advanced	Open Active	2019-09-24	NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-03-27	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
INST 96144	Ill Defined	Open Active	2013-06-04	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
Pharm CA209901	GU Other	Open Active	2019-06-11	Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
SWOG S1815	GI Other	Open Active	2020-06-22	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
SWOG S0820	GI Colorectal Prevention	Open Active	2017-11-29	SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Alliance A021502	GI Colorectal Adjuvant	Open Active	2020-01-14	Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S1900A	Lung NSCLC Advanced	Open Active	2020-06-25	SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1800A	Lung NSCLC Advanced	Open Active	2020-04-08	SWOG S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-03-26	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-04-21	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-C1	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131-Z1C	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-M	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
Alliance A011401	Supportive	Open Active	2016-11-01	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Presbyterian Rust Medical Center

Trial #	Type	Study Status	Status Date	Title
Alliance A011202	Breast Adjuvant	Open Active	2020-05-27	Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Alliance A011502	Breast Adjuvant	Open Active	2018-04-19	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-03-27	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
NRG Oncology NRG-BR004	Breast Advanced	Open Active	2019-09-24	NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-10-02	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Alliance A021502	GI Colorectal Adjuvant	Open Active	2020-01-14	Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
SWOG S1703	Breast Other	Open Active	2020-03-02	SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
SWOG S0820	GI Colorectal Prevention	Open Active	2018-09-14	SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
GOG 0263	GYN Cervical Adjuvant	Open Active	2018-06-07	GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
SWOG S1815	GI Other	Open Active	2020-06-22	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
INST 96144	Ill Defined	Open Active	2018-04-10	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-08-04	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-04-05	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG S1800A	Lung NSCLC Advanced	Open Active	2020-04-08	SWOG S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
SWOG S1900A	Lung NSCLC Advanced	Open Active	2020-06-24	SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
Alliance A011401	Supportive	Open Active	2018-04-19	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Southwest Gynecologic Oncology Associates

Trial #	Type	Study Status	Status Date	Title
RTOG 0724/GOG-0724	GYN Cervical Adjuvant	Open Active	2015-10-30	RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263	GYN Cervical Adjuvant	Open Active	2010-12-02	GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Pharm C-750-01/GOG-3028	GYN Cervical Advanced	Open Active	2020-02-13	Agenus C-750-01/GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (antiPD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
GOG-3026	GYN Ovarian Advanced	Open Active	2020-03-27	GOG-3026: A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
NRG Oncology NRG-GY005	GYN Other	Open Active	2019-11-06	NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
GOG 0238	GYN Uterine Advanced	Open Active	2015-08-24	GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Pharm 3000-02-006	GYN Ovarian Advanced	Open Active	2020-02-06	Tesaro 3000-02-006: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-C1	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-M	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1C	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
DCP-001A	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DCP-001B	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001D	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001C	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********

UNM - CRTC

Trial #	Type	Study Status	Status Date	Title
Alliance A071701	Brain Advanced	Open Active	2020-04-17	Alliance A071701: Genomically-Guided Treatment Trial in Brain Metastases
Pharm LNS-101	Advanced Solid Tumors	Open Active	2019-10-11	Linnaeus Therapeutics LNS-101: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer
Alliance A071801	Brain Advanced	Open Active	2020-06-11	Alliance A071801: Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
NRG Oncology NRG-BN003	Brain Other	Open Active	2017-10-20	NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
NCCTG N0577	Brain Advanced	Open Active	2017-12-18	NCCTG N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
Alliance A011502	Breast Adjuvant	Open Active	2017-05-03	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Alliance A011202	Breast Adjuvant	Open Active	2020-05-27	Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
ECOG-ACRIN EA1131	Breast Adjuvant	Open Active	2019-01-15	ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
SWOG S1418/BR006	Breast Adjuvant	Open Active	2020-03-27	SWOG S1418/BR006: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
NSABP B-51	Breast Adjuvant	Open Active	2016-08-01	NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP-B-51/RTOG-1304)
Alliance Foundation Trials AFT-38	Breast Advanced	Open Active	2018-03-28	Alliance Foundation Trials AFT-38: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Alliance A221505	Breast Advanced	Open Active	2018-04-10	Alliance A221505: Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation With Breast Reconstruction
NRG Oncology NRG-BR004	Breast Advanced	Open Active	2019-09-24	NRG Oncology NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
INST University of Arizona 1807	Breast Advanced	Open Active	2019-10-24	INST University of Arizona 1807: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
Novartis CBYL719X2402	Breast Advanced	Open Active	2020-05-19	Novartis CBYL719X2402: A Phase II, Multicenter, Open-label, Two-cohort, Noncomparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients with PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), who have Progressed on or after CDK 4/6 Inhibitor Treatment
Pharm SGNLVA-001	Breast Advanced	Open Active	2017-09-26	Seattle Genetics, Inc. SGNLVA-001: A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of SGN-LIVIA in Patients with LIV-1-Positive Metastatic Breast Cancer
Pharm RAD1901-308	Breast Advanced	Open Active	2019-12-06	Radius Pharmaceuticals RAD1901-308: Elacestrant Monotherapy for the Treatment of ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial
CCTG MA.39	Breast Neoadjuvant	Open Active	2018-09-05	CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer
Pharm SGNLVA-002	Breast Advanced	Open Active	2018-02-20	Seattle Genetics SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
EA1181	Breast Neoadjuvant	Open Active	2020-05-14	EA1181 -The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
UNM 1607	Breast Neoadjuvant	Open Active	2018-04-16	INST UNM 1607: Monitoring response to neoadjuvant chemotherapy (NAC) in Early Stage Breast Cancer (ESBC) Using High-speed MR Spectroscopic Imaging (MRSI)
SWOG S1706	Breast Neoadjuvant	Open Active	2019-06-24	SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
ECOG-ACRIN EA1151	Breast Other	Open Active	2018-08-31	ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST)
Alliance Foundation Trials AFT-25	Breast Other	Open Active	2018-02-07	Alliance Foundation Trials AFT-25: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
SWOG S1703	Breast Other	Open Active	2020-03-02	SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
INST 1311	Epidemiological	Open Active	2013-02-04	INST 1311: A Prospective Birth Cohort Study Involving Environmental Uranium Exposure in the Navajo Nation
CIBMTR Protocol for a Research Database	Epidemiological	Open Active	2017-06-29	CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
UNM TCCP	Epidemiological	Open Active	2017-12-08	INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
UNM 1803	Epidemiological	Open Active	2018-06-26	INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative
Alliance A021502	GI Colorectal Adjuvant	Open Active	2018-10-12	Alliance A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
INST UNM 1809	GI Colorectal Prevention	Open Active	2018-12-27	INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States
Alliance A021703	GI Colorectal Advanced	Open Active	2020-03-03	Alliance A021703: Randomized Double-blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
PHARM CP-MGAH22-06	GI Gastric Advanced	Open Active	2020-03-13	MacroGenics CP-MGAH22-06: A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-nave, HER2-Positive Gastric or Gastroesophageal Junction Cancer
SWOG S0820	GI Colorectal Prevention	Open Active	2017-10-05	SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer,Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Pharm 937-00	GI Hepatic Adjuvant	Open Active	2020-02-04	Merck 937-00: A Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
Alliance A021602	GI Other	Open Active	2019-05-08	Alliance A021602: Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)
Pharm XL184-312	GI Hepatic Advanced	Open Active	2019-10-31	Exelixis XL184-312: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
INST Dana-Farber Cancer Institute 18-128	GI Other	Open Active	2019-07-15	INST Dana-Farber Cancer Institute 18-128: EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options - RCT of Usual Chemotherapy Educational Tools versus Investigational Chemotherapy Educational Tools
ECOG-ACRIN EA2165	GI Other	Open Active	2019-04-08	ECOG-ACRIN EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
NRG-GI005	GI Other	Open Active	2020-06-03	NRG-GI005: Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
UNM 1603	GI Other	Open Active	2016-11-30	INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health
SWOG S1815	GI Other	Open Active	2020-06-22	SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Pharm 905-00	GU Other	Open Active	2020-02-04	Merck 905-00: A Phase 3 Randomized Study of Cystectomy plus Peri-operative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Patients with Muscle-invasive Bladder Cancer (KEYNOTE-905)
Pharm 866-00	GU Other	Open Active	2019-11-04	Merck 866-00: A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
Pharm CA209901	GU Other	Open Active	2019-06-11	Bristol-Myers Squibb CA209-901: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Pharm PrTK03	GU Prostate Adjuvant	Open Active	2017-06-28	Advantagene PrTK03: A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
UNM 1805	GU Other	Open Active	2019-01-08	INST UNM 1805: Trait Mindfulness in Distressed New Mexico Prostate Cancer Survivors
Alliance A031704	GU Renal Cell Advanced	Open Active	2019-11-26	Alliance A031704: PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated REnal cell cancEr (PDIGREE)
Pharm 1205-201	GU Prostate Advanced	Open Active	2018-08-01	Constellation Pharmaceuticals 1205-201: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Pharm 010-00	GU Prostate Advanced	Open Active	2020-02-10	Merck 010-00: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) PlusOlaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
NRG Oncology NRG-GU005	GU Prostate Advanced	Open Active	2018-01-29	NRG Oncology NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Alliance Foundation Trials AFT-19	GU Prostate Advanced	Open Active	2017-12-19	Alliance Foundation Trials AFT-19: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NRG Oncology NRG-GY005	GYN Other	Open Active	2019-06-24	NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Pharm C-750-01/GOG-3028	GYN Cervical Advanced	Open Active	2019-11-14	Agenus C-750-01/GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (antiPD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
NRG Oncology NRG-GY006	GYN Cervical Advanced	Open Active	2020-02-18	NRG Oncology NRG-GY006: A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
RTOG 0724/GOG-0724	GYN Cervical Adjuvant	Open Active	2015-07-23	RTOG 0724/GOG-0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263	GYN Cervical Adjuvant	Open Active	2010-10-20	GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
GOG-3026	GYN Ovarian Advanced	Open Active	2020-03-27	GOG-3026: A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
UNM 1509	GYN Other	Open Active	2020-06-29	INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
VBL Therapeutics VB-111-701/GOG 3018	GYN Ovarian Advanced	Open Active	2019-08-29	VBL Therapeutics VB-111-701/GOG 3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Pharm 3000-02-006	GYN Ovarian Advanced	Open Active	2020-02-06	Tesaro 3000-02-006: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
NRG-GY021	GYN Ovarian Advanced	Open Active	2020-01-28	NRG-GY021: A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
INST 0551C	Hematology Acute Leukemia	Open Active	2016-05-02	INST 0551C, Project 4 Dynamic Analysis of Signaling Networks in Leukemia
Alliance A041501	Hematology Acute Leukemia	Open Active	2020-04-03	Alliance A041501: A PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN (A CONJUGATED ANTI-CD22 MONOCLONAL ANTIBODY) TO FRONTLINE THERAPY IN YOUNG ADULTS (AGES 18-39 YEARS) WITH NEWLY DIAGNOSED PRECURSOR B-CELL ALL
NRG Oncology NRG-HN004	Head And Neck Advanced	Open Active	2019-03-20	NRG Oncology NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
INST 1310	Head And Neck Advanced	Open Active	2015-02-25	INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
ECOG-ACRIN EA3161	Head And Neck Advanced	Open Active	2020-02-06	ECOG-ACRIN EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
GOG 0238	GYN Uterine Advanced	Open Active	2015-08-24	GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
ECOG-ACRIN E4412	Hematology Lymphoma Hodgkins	Open Active	2020-03-13	ECOG-ACRIN E4412: A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
SWOG S1712	Hematology Chronic Leukemia	Open Active	2019-02-21	SWOG S1712: A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease
Alliance A041702	Hematology Chronic Leukemia	Open Active	2019-06-14	Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Pharm TPI-ALV-202	Hematology Acute Leukemia	Open Active	2020-06-26	Tolero Pharmaceuticals TPI-ALV-202: A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax Combination Therapy
UNM 1512	Hematology Acute Leukemia	Open Active	2018-05-23	INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS
Pharm 63935937MDS3001	Hematology Other	Open Active	2020-06-26	Geron 63935937MDS3001: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
ECOG-ACRIN NHLBI-MDS	Hematology Other	Open Active	2020-05-18	ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History
SWOG S1803	Hematology Myeloma	Open Active	2019-11-14	SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Alliance A061202	Hematology Myeloma	Open Active	2018-10-03	Alliance A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
SWOG S1608	Hematology Lymphoma Non-Hodgkins	Open Active	2019-12-16	SWOG S1608: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
SWOG S1826	Hematology Lymphoma Hodgkins	Open Active	2020-05-08	SWOG S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Pharm INCB 18424-MA-GD-301	Hematology Stem Cell Transplant	Open Active	2019-01-29	Incyte INCB 18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
UNM 1709	Ill Defined	Open Active	2019-05-30	INST UNM 1709: Facilitating enrollment Of community cancer patientS on Therapeutic clinical trials using project ECHO Resources (FOSTER)
SWOG S1609	Ill Defined	Open Active	2019-12-10	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
INST 1306	Ill Defined	Open Active	2015-01-01	INST 1306: Whole Genome Sequencing of Human Cancer Tissues
Alliance A151216	Lung NSCLC Adjuvant	Open Active	2016-05-09	Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
SWOG S1900C	Lung NSCLC Advanced	Open Active	2020-05-05	SWOG S1900C: A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-Study)
SWOG S1900A	Lung NSCLC Advanced	Open Active	2019-03-14	SWOG S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1800A	Lung NSCLC Advanced	Open Active	2020-04-08	SWOG S1800A: A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
SWOG LungMAP	Lung NSCLC Advanced	Open Active	2019-03-14	SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)
ECOG-ACRIN E4512	Lung NSCLC Adjuvant	Open Active	2019-03-01	ECOG-ACRIN E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
ECOG-ACRIN EA6134	Skin Melanoma Advanced	Open Active	2020-01-03	ECOG-ACRIN EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
ECOG-ACRIN EAY131	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
SWOG S1801	Skin Melanoma Advanced	Open Active	2020-04-03	SWOG S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable State III-IV High Risk Melanoma
Alliance A091802	Skin Melanoma Advanced	Open Active	2019-12-06	Alliance A091802: Phase II Randomized Trial of Avelumab Plus Cetuximab versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
NRG-LU005	Lung SCLC Adjuvant	Open Active	2020-02-05	NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
SWOG S1616	Skin Melanoma Advanced	Open Active	2019-07-02	SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent
ECOG-ACRIN EAY131-A	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-C2	Solid Tumors Other	Open Active	2019-03-15	ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-C1	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-L	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-V	Solid Tumors Other	Open Active	2017-07-26	ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-T	Solid Tumors Other	Open Active	2019-08-26	ECOG-ACRIN EAY131-T: Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-M	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-Z1E	Solid Tumors Other	Open Active	2019-11-15	ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1C	Solid Tumors Other	Open Active	2020-05-07	ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-Z1K	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1K: Match Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
Pharm SGNS40-001	Solid Tumors Other	Open Active	2019-12-18	Seattle Genetics SGNS40-001: A Phase I, Open-label Dose Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies
ECOG-ACRIN EAY131-Z1L	Solid Tumors Other	Open Active	2019-07-29	ECOG-ACRIN EAY131-Z1L: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600E BRAF Mutations
Pharm R3767-ONC-1613	Solid Tumors Other	Open Active	2017-12-15	Regeneron Pharmaceuticals R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies
ECOG-ACRIN EAY131-Z1G	Solid Tumors Other	Open Active	2019-09-16	ECOG-ACRIN EAY131-Z1G: MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result
Alliance A011401	Supportive	Open Active	2016-10-02	Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
DCP-001C	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001B	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001A	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********
DCP-001	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Alliance A151804	Supportive	Open Active	2020-06-15	Alliance A151804: Establishment of a National Biorepository to Advance Studies of Immune-related Adverse Events
WFU WF 97115	Supportive	Open Active	2017-07-06	WFU WF 97115: A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
WFU WF-1801	Supportive	Open Active	2019-09-27	Wake Forest WF-1801: A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
INST Johns Hopkins Hospital 1802	Supportive	Open Active	2019-09-20	INST Johns Hopkins Hospital 1802: A Multi-Center Randomized Control Trial of Perioperative Palliative Care Surrounding Surgery for Patients and Their Family Members
ECOG-ACRIN E1Q11	Supportive	Open Active	2018-04-18	ECOG-ACRIN E1Q11: EROS: Engendering Reproductive Health within Oncologic Survivorship
DCP-002	Supportive	Open Active	2017-11-16	NCI DCP-002: Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations
DCP-001D	Supportive	Open Active	2016-08-17	Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)**This is for additional enrollments. Enter the Study Number in the patient status notes.*********

Women's Cancer and Surgical Care

Trial #	Type	Study Status	Status Date	Title
INST 96144	Ill Defined	Open Active	2018-06-13	INST City of Hope 96144: Molecular Genetics Studies of Cancer Patients and Their Relatives

Latest Updates

Clinical Trials Available in New Mexico

Type of Cancer Clinical Trial Site

Cancer Support and Treatment Directory
English
Spanish

Christus St Vincent Regional Cancer Center

Lovelace Medical Center-Saint Joseph Square

Lovelace Radiation Oncology

Lovelace Respiratory Research Institute

Lovelace Women's Hospital

Memorial Medical Center

New Mexico Oncology Hematology Consultants

NMOHC Gallup

Presbyterian Medical Group

Presbyterian Rust Medical Center

Southwest Gynecologic Oncology Associates

UNM - CRTC

Women's Cancer and Surgical Care

Latest Updates

Clinical Trials Available in New Mexico

Cancer Support and Treatment Directory

English

Spanish